Valley National Advisers Inc. Has $201,000 Position in GlaxoSmithKline plc (GSK)
Valley National Advisers Inc. lessened its stake in shares of GlaxoSmithKline plc (NYSE:GSK) by 39.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,656 shares of the pharmaceutical company’s stock after selling 3,746 shares during the period. Valley National Advisers Inc.’s holdings in GlaxoSmithKline were worth $201,000 at the end of the most recent reporting period.
A number of other hedge funds also recently bought and sold shares of the stock. Haverford Financial Services Inc. increased its position in GlaxoSmithKline by 91.7% during the 4th quarter. Haverford Financial Services Inc. now owns 10,722 shares of the pharmaceutical company’s stock valued at $380,000 after buying an additional 5,128 shares in the last quarter. Haverford Trust Co. increased its position in GlaxoSmithKline by 16.5% during the 4th quarter. Haverford Trust Co. now owns 867,536 shares of the pharmaceutical company’s stock valued at $30,771,000 after buying an additional 122,945 shares in the last quarter. Landscape Capital Management L.L.C. increased its position in GlaxoSmithKline by 15.3% during the 4th quarter. Landscape Capital Management L.L.C. now owns 28,129 shares of the pharmaceutical company’s stock valued at $998,000 after buying an additional 3,737 shares in the last quarter. Burney Co. increased its position in GlaxoSmithKline by 35.9% during the 4th quarter. Burney Co. now owns 8,472 shares of the pharmaceutical company’s stock valued at $301,000 after buying an additional 2,240 shares in the last quarter. Finally, Icon Wealth Partners LLC bought a new position in GlaxoSmithKline during the 4th quarter valued at approximately $393,000. 9.17% of the stock is owned by institutional investors.
A number of research analysts recently weighed in on the company. Zacks Investment Research lowered GlaxoSmithKline from a “hold” rating to a “sell” rating in a research report on Wednesday, February 21st. Cowen reaffirmed a “hold” rating and set a $40.00 price objective on shares of GlaxoSmithKline in a research report on Thursday, February 15th. Kepler Capital Markets raised GlaxoSmithKline from a “reduce” rating to a “hold” rating in a research report on Friday, February 9th. TheStreet lowered GlaxoSmithKline from a “b-” rating to a “c” rating in a research report on Wednesday, February 7th. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of GlaxoSmithKline in a research report on Monday, February 5th. Three equities research analysts have rated the stock with a sell rating, nine have given a hold rating and five have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $38.97.
GlaxoSmithKline (NYSE:GSK) last posted its earnings results on Wednesday, February 7th. The pharmaceutical company reported $0.72 EPS for the quarter, topping the Zacks’ consensus estimate of $0.69 by $0.03. The business had revenue of $10.14 billion during the quarter, compared to analyst estimates of $9.89 billion. GlaxoSmithKline had a return on equity of 130.63% and a net margin of 4.97%. sell-side analysts expect that GlaxoSmithKline plc will post 2.95 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, April 12th. Shareholders of record on Friday, February 23rd will be issued a $0.633 dividend. This is a positive change from GlaxoSmithKline’s previous quarterly dividend of $0.50. The ex-dividend date of this dividend is Thursday, February 22nd. This represents a $2.53 dividend on an annualized basis and a dividend yield of 6.99%. GlaxoSmithKline’s dividend payout ratio (DPR) is presently 320.26%.
COPYRIGHT VIOLATION NOTICE: “Valley National Advisers Inc. Has $201,000 Position in GlaxoSmithKline plc (GSK)” was reported by Daily Political and is owned by of Daily Political. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.dailypolitical.com/2018/03/03/valley-national-advisers-inc-has-201000-position-in-glaxosmithkline-plc-gsk.html.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.